"Quinolones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.
| Descriptor ID |
D015363
|
| MeSH Number(s) |
D03.633.100.810.835
|
| Concept/Terms |
Quinolones- Quinolones
- Quinolinones
- Ketoquinolines
- Oxoquinolines
|
Below are MeSH descriptors whose meaning is more general than "Quinolones".
Below are MeSH descriptors whose meaning is more specific than "Quinolones".
This graph shows the total number of publications written about "Quinolones" by people in this website by year, and whether "Quinolones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 |
| 1997 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 4 | 1 | 5 |
| 2009 | 2 | 1 | 3 |
| 2010 | 5 | 0 | 5 |
| 2011 | 4 | 0 | 4 |
| 2012 | 0 | 3 | 3 |
| 2013 | 2 | 2 | 4 |
| 2014 | 2 | 0 | 2 |
| 2017 | 5 | 1 | 6 |
| 2018 | 2 | 0 | 2 |
| 2020 | 2 | 0 | 2 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quinolones" by people in Profiles.
-
Potentiating the radiation-induced type I interferon antitumoral immune response by ATM inhibition in pancreatic cancer. JCI Insight. 2024 Feb 20; 9(6).
-
Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization. Sci Transl Med. 2024 Feb 14; 16(734):eadj5962.
-
Papilledema and hypervitaminosis A after elexacaftor/tezacaftor/ivacaftor for cystic fibrosis. Can J Ophthalmol. 2022 02; 57(1):e6-e10.
-
Local Anti-PD-1 Delivery Prevents Progression of Premalignant Lesions in a 4NQO-Oral Carcinogenesis Mouse Model. Cancer Prev Res (Phila). 2021 08; 14(8):767-778.
-
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors. Invest New Drugs. 2021 08; 39(4):1089-1098.
-
Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. Clin Cancer Res. 2021 04 01; 27(7):1864-1874.
-
A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation. J Cyst Fibros. 2021 03; 20(2):234-242.
-
Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients. J Cyst Fibros. 2021 03; 20(2):333-338.
-
A PIK3CA transgenic mouse model with chemical carcinogen exposure mimics human oral tongue tumorigenesis. Int J Exp Pathol. 2020 02; 101(1-2):45-54.
-
A Dilute and Shoot LC-MS/MS Method for Antipsychotics in Urine. J Anal Toxicol. 2020 May 18; 44(4):331-338.